Kuwait Pharmaceuticals and Healthcare Report Q3 2011

  • ID: 1844170
  • June 2011
  • Region: Kuwait
  • 91 Pages
  • Business Monitor International

Business Monitor International's Kuwait Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Kuwait's pharmaceuticals and healthcare industry.

BMI View: Kuwait remains one of the most attractive regional markets for pharmaceutical investors. Its affluent population has traditionally had a preference for patented medicines, which comprise over 67% of the total market’s value. Epidemiological factors, particularly the rising prevalence of diabetes and similar chronic diseases, will continue to drive market growth. We expect the annual pharmaceutical values growth in Kuwait to outstrip that of inflation, indicating continued commercial opportunities for drugmakers.

Headline Expenditure Projections
- Pharmaceuticals: KWD259mn (US$905mn) in 2010 to KWD286mn (US$1.02bn) in 2011; +10.7% in local currency terms and +13.0% in US dollar terms. Forecast up moderately from Q211 due to macroeconomic factors.
- Healthcare: KWD834mn (US$2.92bn) in 2010 to KWD922mn (US$3.29bn) in 2011; +10.5% READ MORE >

Note: Product cover images may vary from those shown

Executive Summary

SWOT Analysis
- Kuwait Pharmaceuticals And Healthcare Industry SWOT
- Kuwait Political SWOT
- Kuwait Economic SWOT
- Kuwait Business Environment SWOT

Pharmaceutical Business Environment Ratings
- Table: Middle East And Africa – Regional Pharmaceutical Business Environment Ratings For Q311
- Rewards
- Risks

Kuwait – Market Summary
- Regulatory Regime
- Foreign Direct Investment Regulations
- Intellectual Property Regime
- IP Shortcomings
- Pricing Regime
- Recent Pricing Regime Developments
- Reimbursement Regime
- Public Procurement of Medicines
- Regional Harmonisation
- Free Trade Agreements
- Industry Developments
- Epidemiology
- Communicable Diseases
- Non-Communicable Diseases
- Healthcare Sector
- Healthcare Staff
- Primary Care
- Secondary Care
- Recent Public Health Developments
- Healthcare Financing
- Healthcare Insurance
- Healthcare Insurance Developments
- Healthcare Reforms
- International Collaboration
- Research And Development
- Biotechnology Sector
- Medical Devices
- Table: Diverse Potential For Product Launches: New Products For 2009

Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors – Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Macroeconomic Forecast
- Table: Kuwait – Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Medical Device Market Forecast
- Table: Medical Devices Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Exports and Imports Indicators 2007-2015
- Other Healthcare Data
- Key Risks To BMI Forecasts

Competitive Landscape
- Pharmaceutical Sector
- Foreign Company Developments

Company Profiles
- Local Companies
- Kuwait-Saudi Pharmaceutical Industries (KSP)
- Advanced Technology Company
- Bader Sultan & Bros
- Safwan Trading And Contracting Company
- Multinationals
- Novartis
- Sanofi-Aventis
- Pfizer
- GlaxoSmithKline
- Merck & Co
- Johnson & Johnson

Country Snapshot: Kuwait Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 1997-2006
- Table: Consumer Expenditure, 2000-2012


BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceuticals Business Environment Ratings
- Risk/Reward Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components

Note: Product cover images may vary from those shown

- Kuwait-Saudi Pharmaceutical Industries (KSP)
- Advanced Technology Company
- Bader Sultan & Bros
- Safwan Trading And Contracting Company

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • Pfizer, Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S